Prognostic impact of biomarkers in PMBCL: rationale for early integration of immune checkpoint inhibitors
These findings suggest that high-risk patients may benefit significantly from the early incorporation of ICIs into their treatment plans.
Authors
- I. A. Shupletsova (ORCID: https://orcid.org/0000-0003-0922-9314)
- Yulia Chabaeva (ORCID: https://orcid.org/0000-0001-8044-598X)
- В. Л. Сурин (ORCID: https://orcid.org/0000-0002-1890-4492)
- Natalya Risinskaya (ORCID: https://orcid.org/0000-0003-2957-1619)
- С. М. Куликов (ORCID: https://orcid.org/0000-0002-6288-7570)
- Runiza Abdurashidova (ORCID: https://orcid.org/0000-0002-5148-8355)
- А. М. Ковригина (ORCID: https://orcid.org/0000-0002-1082-8659)
- Е. Е. Звонков (ORCID: https://orcid.org/0000-0002-2639-7419)
- Andrey Sudarikov (ORCID: https://orcid.org/0000-0001-9463-9187)
- Т. Н. Обухова (ORCID: https://orcid.org/0000-0003-1613-652X)
- Ya K Mangasarova (ORCID: https://orcid.org/0000-0003-1936-5934)
- А. У. Магомедова (ORCID: https://orcid.org/0000-0003-4263-8275)
- Bella Biderman (ORCID: https://orcid.org/0000-0002-6253-3334)
- Т В Абрамова (ORCID: https://orcid.org/0000-0003-3163-4930)
- Rasul I. Iusupov
- Lena E. Nikulina (ORCID: https://orcid.org/0000-0003-3914-8611)
Institutions
- Sechenov University (RU)
- Lomonosov Moscow State University (RU)
- National Medical Research Center for Hematology (RU)
Publication Details
- Journal
- Exploration of Targeted Anti-tumor Therapy
- Published
- 2025-05-20
- DOI
- https://doi.org/10.37349/etat.2025.1002318
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00